U01AI150589

Dietary and Synbiotic Strategy to Limit Gut Microbiome Dysbiosis and Protect Against Clostridioides difficile Infection - Summary

Clostridioides difficile infection (CDI) is an important cause of morbidity and mortality, and rates are on the rise. This indicates that safe and new approaches are urgently needed for treatment and prevention. Emerging evidence suggests that a high-fat/low-fiber diet may promote CDI. Diets high in saturated fat lead to the production of primary bile acids that can promote infection by germinating C. difficile spores. Diets deficient in fiber perpetuate C. difficile colonization in mice, and this effect was linked, at least in part, with a loss of short-chain fatty acids (SCFAs).

Our preliminary murine studies show that a high-fat/low-fiber diet resulted in increased microbiome disturbance following broad-spectrum antibiotic challenge. It also led to increased cecal levels of primary bile acids that germinate C. difficile spores, markedly decreased levels of secondary bile acids that can kill C. difficile, and increased morbidity and mortality upon C. difficile exposure. These results suggest that dietary intervention has promise for preventing CDI in individuals at high risk.

Aim 1A will determine the effects of dietary levels of fat and fiber in preventing antibiotic-induced gut microbiome disturbance and CDI, using conventional mice fed varied diets. Aim 1B will directly evaluate the role of increased intestinal levels of primary bile acids in the increased C. difficile pathogenicity by chemically inhibiting the ileal apical sodium-dependent bile salt transporter.

Oncology patients have a high incidence of CDI, driven by risk factors that include frequent hospitalization, antibiotic use, and use of chemotherapeutic drugs. Aim 2 will test a higher-fiber/lower-fat dietary intervention for the prevention of C. difficile recurrence and maintenance of gut microbiome diversity in oncology patients. Production of SCFAs may be one mechanism contributing to the protective effects of fiber in CDI. Metabolism of the SCFA butyrate by intestinal epithelial cells plays a key role in the establishment of intestinal hypoxia, which is important because reversion to hypoxia is a key process in promoting the reestablishment of an anaerobe-dominated complex gut microbiome following disturbance.

SCFA production from fiber is limited in individuals with a low complexity facultative anaerobe-dominated microbiome, which is common in individuals with recurrent CDI. In our earlier work, we have identified butyrate-producers, including Clostridium symbiosum and Anaerostipes caccace, that specialize in infant and disturbed guts. They can produce butyrate using a simple substrate, gluconic acid, as a sole source of carbon. Thus, in Aim 3, we will test the hypothesis that synbiotic treatment with disturbance-adapted butyrate-producers and gluconic acid will increase butyrate production, increase intestinal hypoxia, and facilitate the activity of anaerobic secondary bile acid producers that prevent CDI. This will be done using mice humanized with a disturbed/low-complexity microbiota.

The Regents Of The Univ. Of Colorado

TO ASSIST PUBLIC AND PRIVATE NONPROFIT INSTITUTIONS AND INDIVIDUALS TO ESTABLISH, EXPAND AND IMPROVE BIOMEDICAL RESEARCH AND RESEARCH TRAINING IN INFECTIOUS DISEASES AND RELATED AREAS, TO CONDUCT DEVELOPMENTAL RESEARCH, TO PRODUCE AND TEST RESEARCH MATERIALS. TO ASSIST PUBLIC, PRIVATE AND COMMERCIAL INSTITUTIONS TO CONDUCT DEVELOPMENTAL RESEARCH, TO PRODUCE AND TEST RESEARCH MATERIALS, TO PROVIDE RESEARCH SERVICES AS REQUIRED BY THE AGENCY FOR PROGRAMS IN INFECTIOUS DISEASES, AND CONTROLLING DISEASE CAUSED BY INFECTIOUS OR PARASITIC AGENTS, ALLERGIC AND IMMUNOLOGIC DISEASES AND RELATED AREAS. PROJECTS RANGE FROM STUDIES OF MICROBIAL PHYSIOLOGY AND ANTIGENIC STRUCTURE TO COLLABORATIVE TRIALS OF EXPERIMENTAL DRUGS AND VACCINES, MECHANISMS OF RESISTANCE TO ANTIBIOTICS AS WELL AS RESEARCH DEALING WITH EPIDEMIOLOGICAL OBSERVATIONS IN HOSPITALIZED PATIENTS OR COMMUNITY POPULATIONS AND PROGRESS IN ALLERGIC AND IMMUNOLOGIC DISEASES. BECAUSE OF THIS DUAL FOCUS, THE PROGRAM ENCOMPASSES BOTH BASIC RESEARCH AND CLINICAL RESEARCH. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM EXPANDS AND IMPROVES PRIVATE SECTOR PARTICIPATION IN BIOMEDICAL RESEARCH. THE SBIR PROGRAM INTENDS TO INCREASE AND FACILITATE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM STIMULATES AND FOSTERS SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. RESEARCH CAREER DEVELOPMENT AWARDS SUPPORT THE DEVELOPMENT OF SCIENTISTS DURING THE FORMATIVE STAGES OF THEIR CAREERS. INDIVIDUAL NATIONAL RESEARCH SERVICE AWARDS (NRSAS) ARE MADE DIRECTLY TO APPROVE APPLICANTS FOR RESEARCH TRAINING IN SPECIFIED BIOMEDICAL SHORTAGE AREAS. IN ADDITION, INSTITUTIONAL NATIONAL RESEARCH SERVICE AWARDS ARE MADE TO ENABLE INSTITUTIONS TO SELECT AND MAKE AWARDS TO INDIVIDUALS TO RECEIVE TRAINING UNDER THE AEGIS OF THEIR INSTITUTIONAL PROGRAM.

93.855 - Allergy and Infectious Diseases Research

National Institute of Allergy and Infectious Diseases (NIAID) [HHS - NIH]

Aurora, Colorado 80045 United States

Single Zip Code

NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required) (PAR-18-633)

Amendment Since initial award the total obligations have increased 400% from $776,329 to $3,880,251.